PDCD1 and Miyoshi myopathy: Although ipilimumab was the first single agent ICI approved by the Food and Drug Administration (FDA) for the treatment of MM [2], different studies provided convincing evidence that anti–PD-1 agents are superior to ipilimumab in terms of OS and progression free survival (PFS) in advanced melanoma patients, for whom durable benefits continue to be observed after a recent 10-year follow-up [3, 4].